Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06503224 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

Study acronym: SCAR02
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 24, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Trial Details
NCT Number NCT06503224
Lead Sponsor The First Affiliated Hospital of University of Science and Technology of China
Conditions
(from sponsor)		 Autoimmune Diseases
Related terms Arthritis, Rheumatoid, Autoimmune Diseases, Lupus Erythematosus, Systemic, Scleroderma, Systemic
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov